Acquired hemophilia A is a rare but severe autoimmune bleeding disorder. It is more
frequent in the elderly and results from the presence of autoantibodies directed against …

Acquired hemophilia A is a rare bleeding diathesis caused by autoantibodies directed
against clotting factor VIII and associated with an increased morbidity and mortality. This …

Normal pregnancy is associated with profound alterations in the coagulation and fibrinolytic
systems. While these physiological procoagulant changes are aimed to minimise …

Rituximab is a monoclonal chimeric antibody to the CD20 antigen, which has proven to be
effective in the treatment of non-Hodgkin lymphomas. Recently, rituximab has also been …

Autoantibodies against plasma coagulation factors could be developed by some individuals
inducing severe and sometimes fatal bleedings. This clinical entity is called acquired …

The development of factor VIII autoantibodies is a rare but severe complication of
pregnancy. Although the natural history of postpartum acquired hemophilia A is usually …

Acquired hemophilia A is a rare bleeding diathesis caused by autoantibodies directed
against clotting factor VIII and associated with an increased morbidity and mortality. This …

Abstract Background About 1%–5% of acquired haemophilia A cases affect mothers in the
postpartum setting. Aims This study delineates the characteristics of this disease, specific to …

Recombinant activated factor VII (rFVIIa,'NovoSeven') is indicated for the treatment of
spontaneous and surgical bleeding in patients with haemophilia A or B with antibodies to …

El desarrollo de autoanticuerpos circulantes que inhiban a los factores de la coagulación
puede generar cuadros hemorrágicos graves y en ocasiones fatales. Esta entidad clínica se …